|
Description:
|
|
Samy Suissa, PhD, of McGill University joins CHEST Podcast Editor, D. Kyle Hogarth, MD, FCCP, for a conversation on the Commentary that he and Amnon Ariel, MD, FCCP, contributed to the May issue. In response to increased asthma death risks with long acting beta-agonists (LABA) in a number of randomized trials, the FDA recently mandated manufacturers to conduct five large non-inferiority randomized trials of LABA plus inhaled corticosteroids. Dr. Suissa gives his thoughts on the challenges of evaluating data from these upcoming studies. (duration: 26:36 min) |